Showing 3841-3850 of 5910 results for "".
- RayOne EMV Toric IOL Approved by Health Canadahttps://modernod.com/news/rayone-emv-toric-iol-approved-by-health-canada/2482626/Rayner announced the approval of RayOne EMV Toric IOL by Health Canada. Developed in collaboration with Professor Graham Barrett, RayOne EMV and RayOne EMV Toric are the only patented aspheric IOLs that induce controlled positive spherical aberration to extend depth of focus, according
- Inflammasome Therapeutics Announces Positive Topline Data from K8 Implant Trial for GAhttps://modernod.com/news/inflammasome-therapeutics-announces-positive-topline-data-from-k8-implant-trial-for-geographic-atrophy/2482621/Inflammasome Therapeutics reported 3-month results from a clinical trial of its K8 implant in patients with geographic atrophy (GA). The study, conducted at the University of Kentucky (NCT06164587), demonstrated significant efficacy and safety following a single inject
- Visible Genomics Wins 2025 AMD Genetic Testing Company of the Year Awardhttps://modernod.com/news/visible-genomics-wins-2025-amd-genetic-testing-company-of-the-year-award/2482619/Visible Genomics, a provider of genetic testing solutions for severe ocular diseases, was named 'Life Sciences Review AMD Genetic Testing Company of the Year 2025.' This award recognizes the company’s innovative contributions to proactive care for advanced age-related macular degene
- AbbVie and Regenxbio Announce Updates on the ABBV-RGX-314 Clinical Program in DR and Wet AMDhttps://modernod.com/news/abbvie-and-regenxbio-announce-updates-on-the-abbv-rgx-314-clinical-program-in-dr-and-wet-amd/2482618/AbbVie and Regenxbio announced updates to the ABBV-RGX-314 gene therapy clinical program. Data from the ATMOSPHERE and ASCENT pivotal trials evaluating the safety and efficacy of the subretinal delivery of ABBV-RGX-314 in patients with wet AMD are expected in 2026. The co
- Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Trial of Linsitinib in Patients with TEDhttps://modernod.com/news/sling-therapeutics-announces-positive-topline-results-from-phase-2b3-lids-trial-of-oral-small-molecule-linsitinib-in-patients-with-ted/2482614/Sling Therapeutics announced topline efficacy and safety data from the phase 2b/3 LIDS trial of linsitinib in patients with active, moderate to severe Thyroid Eye Disease (TED). Linsitinib, Sling’s lead product candidate, is an oral small molecule, taken twice-daily
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the
- Bausch + Lomb Launches enVista Aspire Monofocal and Toric IOLs in the European Unionhttps://modernod.com/news/bausch-lomb-launches-envista-aspire-monofocal-and-toric-iols-in-the-european-union/2482610/Bausch + Lomb announced the commercial launch of the enVista Aspire monofocal and toric IOLs in the European Union after receiving a CE Mark late last year. According to B+L, enVista Aspire combines 'intermediate optimized' optics, which are designed for a broader dept
- Alkeus Announces Interim TEASE-3 Study Results Evaluating Gildeuretinol in Early-Stage Stargardt Patientshttps://modernod.com/news/alkeus-announces-new-interim-tease-3-study-results-showing-gildeuretinol-prevented-disease-progression-in-early-stage-stargardt-patients/2482608/Alkeus Pharmaceuticals announced positive interim data from its TEASE-3 study demonstrating that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years. “Thes
- Altris AI Introduces AI-Powered Fluid and GA Quantification Featureshttps://modernod.com/news/altris-ai-introduces-ai-powered-fluid-and-ga-quantification-features/2482606/Altris AI, which utilizes artificial intelligence for OCT scan analysis, has unveiled additional quantification features for fluids and geographic atrophy (GA) tracking on its web platform. Altris AI currently detects more than 70 retina pathologies and biomarkers. The platform'
- Atsena Therapeutics Initiates Part B of Phase 1/2 Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-initiates-part-b-of-phase-12-clinical-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482602/Atsena Therapeutics announced the initiation of Part B of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s n